Cole is excited to connect with fellow attendees for conversations on collaboration, advances in preclinical toxicology and how the Endpoint Network is supporting various toxicology programs world-wide.

Why Attend and Why We’ll Be There: The ACT Annual Meeting brings together scientists driving the next generation of safety science — where translational precision meets regulatory rigor.

For Endpoint, ACT is more than a networking event. It’s an opportunity to collaborate with the toxicology community on how integrated, on-site preclinical expertise can accelerate timelines, improve reproducibility, and elevate scientific quality.

We’ll be in Phoenix to:

• Advance Translational Alignment: Explore how refined surgical and vascular models can improve prediction of safety outcomes in IND-enabling studies.
  
• Showcase On-Site Production-Level Work: Discuss how Endpoint’s expert teams perform production-level surgical programs directly within client facilities, bringing precision, scalability, and consistency to high-volume preclinical research. Conducting work on-site eliminates transport stress, minimizes procedural variability, and shortens study startup timelines.
  
• Elevate Study Design: Examine how surgical leadership, imaging integration, and expert-driven data interpretation enhance the rigor and reproducibility of toxicology workflows.
• Strengthen Collaboration: Engage with toxicologists, study directors, and regulatory scientists committed to advancing reliable, welfare-conscious research.

We look forward to meaningful conversations with peers in toxicology and safety science — and to sharing ideas that help move high-quality preclinical research forward.

See you in Phoenix!